Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis

Nerre Therapeutics Ltd.80 enrolled

Overview

ORV-PF-01 is a two way, placebo controlled, cross-over study, to evaluate the effect of two doses of orvepitant on cough in patients with IPF.

The study will be a multi-center, double-blind, randomised, placebo-controlled 2-period cross-over study in subjects with chronic cough due to idiopathic pulmonary fibrosis (IPF). Subjects will participate in one of two cohorts (Cohort 1 and Cohort 2). Cohort 1 will evaluate a 30 mg orvepitant dose and Cohort 2 the 10 mg dose. Within each cohort, subjects will be randomised to receive either orvepitant or placebo in the first treatment period (Treatment Period A) followed by the alternate treatment in Treatment Period B. There will be a wash-out period of 3 weeks between the two treatment periods. Subjects will be randomised 1:1 to each of the two treatment orders and 1:1 to each cohort. Subjects will enter a screening period of between 14 and 28 days to determine eligibility. Eligible subjects will be randomised at the Baseline visit and will participate in two identical 28 day treatment periods with the wash-out period between them. There will be a total of 8 visits including the Screening, Baseline and final Follow-up visits.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Cough Idiopathic Pulmonary Fibrosis

Interventions

Orvepitant MaleateDRUG

Orvepitant tablets 30mg or 10mg

PlaceboDRUG

Placebo tablets to match orvepitant 30mg and 10mg tablets

Eligibility

Sex: ALLMin age: 40 Years

Medical Language ↔ Plain English

Key Inclusion Criteria: * Diagnosis of IPF established according to the 2018 or 2022 joint ATS/ERS/JRS/ALAT Clinical Practice Guideline * FEV1/FVC ratio ≥0.65 at the screening visit * Haemoglobin-corrected diffusion capacity of carbon monoxide (Hb-corrected DLCO) ≥25% within 12 months of the screening visit * Arterial oxygen saturation on room air or oxygen ≥90% at Screening * Life expectancy of at least 12 months * Cough that is attributed to IPF, which has not responded to anti-tussive treatment, and which has been present for at least 8 weeks prior to Screening * Mean daily IPF Coughing Severity Scale score ≥5 (after rounding) during the second week of the baseline assessment period Key Exclusion Criteria: * Recent respiratory tract infection (\<8 weeks prior to Screening) * Recent acute exacerbation of IPF (\<8 weeks prior to Screening) * Current smokers or ex-smokers with \<6 months' abstinence prior to Screening * Emphysema ≥50% on high-resolution computed tomography, or the extent of emphysema is greater than the extent of fibrosis according to the reported results of the most recent scan * Mean early morning cough scale score ≥5 and rest of the day cough scale score \<5 (after rounding) during the second week of the baseline assessment period (assessed at Visit 2) * Cough that is predominantly productive in nature and attributable to lung pathology such as chronic bronchitis or bronchiectasis

Locations (37)

Outcomes

Primary Outcomes

Mean Change From Baseline in Weekly Average of the Daily Idiopathic Pulmonary Fibrosis Coughing Severity Scale (IPF CSS)

A numerical rating scale from 0 (no coughing) to 10 (coughing as bad as you can imagine) for coughing severity in the last 24 hours

Time frame: Week 4

Secondary Outcomes

Mean Change From Baseline in Weekly Average of the Early Morning IPF Coughing Severity Scale

A numerical rating scale from 0 (no coughing) to 10 (coughing as bad as you can imagine) for coughing severity first thing in the morning

Time frame: Week 4

Mean Change From Baseline in Weekly Average of the Rest of the Day IPF Coughing Severity Scale

A numerical rating scale from 0 (no coughing) to 10 (coughing as bad as you can imagine) for severity of any other coughing during the last 24 hours, excluding coughing first thing in the morning

Time frame: Week 4

Mean Change From Baseline in Weekly Average of the Daily Urge to Cough Scale

A numerical rating scale from 0 (no urge to cough) to 10 (urge to cough as bad as you can imagine) for severity of urge to cough in the last 24 hours

Time frame: Week 4

Mean Change From Baseline in Weekly Average of the Daily Cough Frequency Scale

A 5-point verbal rating scale for cough frequency over the last 24 hours with response options from 'never' to 'all the time'. The verbal responses were converted to a number (0 = never, 4 = all the time).

Time frame: Week 4

Mean Change From Baseline in Weekly Average of the Daily Dyspnoea Scale

A numerical rating scale from 0 (no shortness of breath) to 10 (shortness of breath as bad as you can imagine) for severity of shortness of breath in the last 24 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

University of Southern California

Los Angeles, California, United States

University of California

San Francisco, California, United States

National Jewish Health

Denver, Colorado, United States

Loyola University Chicago

Maywood, Illinois, United States

Jadestone Clinical Research, LLC

Silver Spring, Maryland, United States

University of Michigan

Ann Arbor, Michigan, United States

Mayo Clinic

Rochester, Minnesota, United States

American Health Research

Charlotte, North Carolina, United States

PulmonIx, LLC

Greensboro, North Carolina, United States

Temple University

Philadelphia, Pennsylvania, United States

...and 27 more locations